摘要
目的 探讨经皮肝穿刺射频热凝联合无水酒精注射治疗肝癌的意义、适应证和疗效评价标准。方法 对共 78个肿瘤结节 ,共进行约 6 0次射频联合无水酒精注射治疗。病人治疗后每个月进行血清标记物检测和B型超声检查。结果 肿瘤结节直径≤ 5cm ,甲胎蛋白定量升高者 ,治疗后甲胎蛋白正常占 72 .0 % (31 / 4 3) ,明显下降占 2 7.9% (1 2 / 4 3)。肿瘤结节直径 >5cm 2例 ,治疗后甲胎蛋白也明显下降 ,2例AFP阴性B型超声复查肿瘤缩小。无手术死亡。结论 经皮肝穿刺射频热凝联合无水酒精注射作为肿瘤治疗的一种方法 。
Objective To discuss the safety and efficacy of percutaneous radiofrequency ablation (PRFA) combined with ethanol injection (EI) to treat liver cancer.Methods Forty five cases of postoperative recrudescent liver cancer with 78 neoplasms were treated with PRFA and EI for 60 times. All patients were examined by B ultrasound and subjected to AFP detection monthly after operation.Results In 43 cases with liver cancer diameter ≤ 5 cm , AFP was normal in 31 cases after operation ( 72.0% ) and 12 cases showed a significantly decreased AFP ( 27.9% ). In 2 cases with liver cancer diameter > 5 cm , AFP was markedly decreased after treatment and no operative death occurred.Conclusion PRFA combined with ethanol injection as a local thermal therapy is a new palliative treatment for hepatic malignancies. It is minimally invasive, safe and effective especially for hepatic tumor postoperative recurrence, or metastases.
出处
《腹部外科》
2004年第3期164-165,共2页
Journal of Abdominal Surgery
